ArticleScientific reports2026
Novel green UPLC method with life cycle assessment for determination of favipiravir and molnupiravir drugs and environmental water samples.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel green UPLC–SPE analytical method was developed for the simultaneous determination of Favipiravir (FVP) and Molnupiravir (MPV) in pharmaceutical and environmental water samples. The method was designed to address the analytical gap surrounding concurrent antiviral monitoring given their co-administration while minimizing solvent consumption, waste generation, and environmental impact. Water samples preparation employed a solid-phase extraction strategy optimized through systematic evaluation of sorbent type, conditioning, washing, and elution steps. Chromatographic separation was achieved using a mobile phase consisting of 0.01 M potassium dihydrogen phosphate buffer (pH 3.5) and 50% methanol (85:15, v/v), delivered at a flow rate of 0.2 mL/min with a 10 µL injection volume. This method produced sharp, well-resolved peaks with a total run time of less than 5 min. The method exhibited excellent linearity (r² ≥ 0.999), accuracy (98.56–101.19%), precision (RSD ≤ 1.8%), and recoveries of (98.97- 100.74%) across tap water, Nile River water, and pharmaceutical wastewater. Greenness was assessed using the Multi-Color Assessment (MA) platform, yielding a final whiteness score of 85.7%, which indicates a well-balanced integration of environmental, practical, analytical, and innovative attributes and supports the method’s suitability for routine application. The Analytical Eco-Scale score (77) and AGREE pictogram score (0.84) further confirm the strong environmental compatibility of the proposed method. Life cycle assessment (LCA) revealed substantial reductions in energy consumption and waste generation compared with conventional HPLC methods. Overall, the proposed UPLC–SPE approach, integrated with LCA and comprehensive greenness evaluation, represents a pioneering and environmentally informed strategy for antiviral analysis and provides a sustainable platform for future pharmaceutical residue monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.